Request Sample Form

Name*:

Phone No.*:

Email*:

Service Intersted In:

Download Complete Report

Your Name*:

Email*:

Contact Number*:

Subject*:

Service Interested In* (required)

Your Requirment*:

Amgen to acquire Otezla® for $13.4 billion in cash

Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain […]

August 26th, 2019|News|

Another Alzheimer’s setback as Amgen, Novartis abandon BACE inhibitor trial

After a review of clinical data from the Generation Program studies, Novartis, Amgen and Banner Alzheimer’s Institute have decided to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer’s Prevention Initiative Generation Program.

July 12th, 2019|News|

Amgen launches AMGEVITATM (Biosimilar Adalimumab) In markets across Europe

“AMGEVITA is Amgen’s second biosimilar to launch in Europe, demonstrating our commitment to providing patients with serious illnesses access to high-quality biological therapies.”

October 17th, 2018|News|

Amgen begins rolling out Humira biosimilar in the EU

Amgevita won European approval back in March 2017 for all indications of its reference product, but Amgen was unable to launch its drug because of a legal battle with AbbVie.

October 16th, 2018|News|